PRELUDE CAPITAL MANAGEMENT, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,165,183
+476.8%
62,847
+522.2%
0.08%
+1166.7%
Q2 2021$202,000
-13.3%
10,1000.0%0.01%0.0%
Q1 2021$233,000
-31.9%
10,100
-27.0%
0.01%
-33.3%
Q4 2020$342,000
+8450.0%
13,830
+13730.0%
0.01%
Q3 2020$4,000
-71.4%
100
-66.7%
0.00%
-100.0%
Q2 2020$14,000
+40.0%
300
+98.7%
0.00%
Q3 2019$10,000
-16.7%
151
-1.9%
0.00%
-100.0%
Q2 2019$12,000
-84.0%
154
-77.2%
0.00%
-75.0%
Q1 2019$75,000
+971.4%
674
+823.3%
0.00%
Q4 2018$7,000
-22.2%
730.0%0.00%
-100.0%
Q3 2018$9,000
-99.2%
73
-99.4%
0.00%
-98.6%
Q2 2018$1,103,000
+981.4%
13,143
+649.3%
0.07%
+677.8%
Q3 2017$102,000
-95.2%
1,754
-90.0%
0.01%
-95.5%
Q2 2017$2,127,000
+1189.1%
17,567
+1103.2%
0.20%
+1156.2%
Q1 2017$165,000
+111.5%
1,460
+192.0%
0.02%
+45.5%
Q4 2014$78,0005000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders